Poland· PL-100310708

Cymevene

A ganciclovir product containing ganciclovirum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AB06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCymeveneATCJ05AB06REGISTER NO.PL-100310708PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Ganciclovir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AB06 (ganciclovir), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Ganciclovir · ATC J05AB06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ganciclovir costs, country by country.

Normalised to the WHO defined daily dose (3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ganciclovir · price per daily dose (3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$494.50
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ganciclovirum
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
J05AB06
ATC class
Ganciclovir
Defined daily dose
3 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909997230139

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

277 interactions on record for ganciclovir.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ganciclovir · interactions on record

277 records

  • 8 severe
  • 194 moderate
  • 75 info

Most severe, free to view

  • CladribineL01BB04severe
  • TrospiumA03AB20moderate
  • Amphotericin BA07AA07moderate
  • NitisinoneA16AX04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ganciclovir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ganciclovir products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Cymevene, Ganciclovir Oresund Pharma
  • Belgium · Cymevene, Virgan
  • Bulgaria · Ганцикловир Ромфарм
  • Czechia · Cymevene, Virgan
  • Germany · Cymeven I.V., Ganciclovir Accord
  • Denmark · Cymevene, Ganciclovir Oresund Pharma
  • Spain · Cymevene, Ganciclovir Accord
  • Finland · Cymevene, Ganciclovir Bioglan
  • France · Cymevan, Ganciclovir Hikma
  • United Kingdom (Northern Ireland) · Cymevene, Ganciclovir Kensington Pharma
  • Greece · Gancilen, Virgan
  • Croatia · Cymevene
  • Hungary · Cymevene, Ganciclovir Rompharm
  • Ireland · Cymevene
  • Italy · Citovirax, Ganciclovir Accord
  • Luxembourg · Cymevene, Virgan
  • Netherlands · Cymevene, Ganciclovir Sandoz
  • Norway · Cymevene, Ganciclovir Bioglan
  • Portugal · Cymevene, Ganciclovir Accord
  • Romania · Ganciclovir Rompharm, Virgan
  • Sweden · Cymevene, Ganciclovir Bioglan
  • Slovakia · Cymevene

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5592369e-2262-4384-941f-d9f8dca68c3a
GET /v1/drugs/5592369e-2262-4384-941f-d9f8dca68c3a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909997230139 ¦ Lz ¦ 89278\n1 fiol.",
  "substance": null,
  "common_name": "Ganciclovirum",
  "pl_product_id": "100310708",
  "pozwolenie_nr": "59/14",
  "auth_procedure": "IR",
  "authorisation_validity": "2029-02-07"
}

See everything about ganciclovir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.